BioWorld

Oct. 6, 2008

Deciphera's B-Raf Inhibitor Program Lands Deal with Lilly

Privately held Deciphera Pharmaceuticals LLC signed its first big pharma deal, licensing rights to four preclinical B-Raf kinase inhibitors to Eli Lilly and Co. for the development of oncology drugs. (BioWorld Today) Read More

Another Case of PML: This Time Raptiva is Implicated

Repros Looks Inside to Close $15.5M Registered Direct Deal

NCI Studying Biomarker Use in Lung Cancer Treatment

Judge Says Amgen Entitled to Permanent Injunction in EPO Case

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...